Takeda Pharmaceutical’s 2025 updates on international regulatory approvals, licensing collaborations, acquisitions and mergers, clinical developments, and financial performance disclosures

Regulatory Approvals: As disclosed on Takeda’s official website in 2025, the status of product approvals includes: Adcetris for Hodgkin lymphoma; Gammagard, HyHub, and HyHub Duo for patients with primary immunodeficiency; Vonvendi for hemophilia; and Takhzyro for hereditary angioedema. Licensing Collaborations: In 2025, Takeda disclosed several licensing collaboration agreements, including partnerships with Innovent Biologics concerning IBI363, IBI343, and IBI3001, as detailed below.

How is Takeda Pharmaceutical performing?

Takeda Pharmaceutical’s FY2025 Highlights Financial Performance: For fiscal year 2025 (April 1, 2025 – March 31, 2026), Takeda reported total revenue of ¥4,505.7 billion, representing a 1.7% decline year-on-year. This decrease was primarily driven by declining sales of products such as Vyvanse/Elvanse. Vyvanse peaked in FY2022 and has since experienced rapid sales erosion. Takeda’s regional revenue breakdown is shown in the chart below. Key patent expirations across Takeda’s portfolio are summarized in the table below. Regulatory Approvals: As disclosed on Takeda’s official website in 2025, the status of product approvals includes: Adcetris for Hodgkin lymphoma; Gammagard, HyHub, and HyHub Duo for patients with primary immunodeficiency; Vonvendi for hemophilia; and Takhzyro for hereditary angioedema. Licensing Collaborations: In 2025, Takeda disclosed licensing collaborations with Innovent Biologics on IBI363, IBI343, and IBI3001: IBI363 is a PD-1/IL-2α bispecific fusion protein intended for non-small cell lung cancer; IBI343 is a Claudin 18.2-targeting antibody–drug conjugate intended for gastric and pancreatic cancers; and IBI3001 is an early-stage bispecific antibody–drug conjugate simultaneously targeting EGFR and B7H3, intended for solid tumors. Clinical Development: In 2025, Takeda advanced several clinical programs, including rusfertide for polycythemia vera; overporexton for type 1 narcolepsy; Phase 3 trials of QDENGA for prevention of dengue virus infection; a Phase 1b trial of subcutaneous mezagitamab (an anti-CD38 monoclonal antibody) for primary immunoglobulin A nephropathy; and a Phase 3 study of zasocitinib (TAK-279) for moderate-to-severe plaque psoriasis. Overall Revenue Performance: Takeda follows a fiscal year running from April 1 to March 31—distinct from the calendar year. Thus, ‘FY’ followed by a year denotes the period from April 1 of that year through March 31 of the following year. Takeda’s core businesses include pharmaceuticals, consumer health, and others. As consumer health financial data were not disclosed in later reporting periods, only consolidated revenue is analyzed here. In years where such data were available, consumer health contributed less than 5% of total revenue. Throughout the analysis period, pharmaceuticals remained Takeda’s dominant revenue driver. Note: All figures in the charts below follow Takeda’s financial reporting units—i.e., billions of Japanese yen. As shown in the chart, FY2019 saw a 57% revenue increase following the acquisition of Shire plc. Total revenue exceeded ¥4 trillion starting in FY2022. In FY2025, total revenue declined slightly to ¥4.5 trillion. Revenue Breakdown by Product Category: Based on annual revenue disclosures per product, Takeda categorizes its pharmaceutical revenues by therapeutic class, as illustrated in the chart below. Products not explicitly listed in Takeda’s annual reports are grouped under ‘Other’.

Dr Reddy's signs India distribution deal for Takeda's Qdenga dengue vaccine

Sep 17, 2026

Dr Reddy's Laboratories signed a distribution deal with Takeda for the Qdenga dengue vaccine in India, which was recently approved for use in children and adults. The vaccine is scheduled to become available in the country during the first half of 2027.

reuters

2026-07-08

Dr Reddy's delays semaglutide supply due to active ingredient issue

2026-09-17

Dr Reddy's signs India distribution deal for Takeda's Qdenga dengue vaccine

Dr Reddy's signs India distribution deal for Takeda's Qdenga dengue vaccine

FAQ